Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provi...
(NYSE: INSP) (“Inspire,” or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that it entered into an accelerated share repurchase (“ASR”) ...
Inspire Medical Systems, Inc. is a medical technology company, which focuses on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. The firm offers inspire therapy, which consists of a remote control and implantable components that ...
Per a report by Fortune Business Insights, the global sleep apnea devices market is projected to grow from $9.70 billion in 2024 to $18.30 billion in 2032 at a CAGR of 8.3%. Factors like the globally increasing incidence of disorders, including cardiovascular disorders and hypertension, and the...
Stock Price177.68 Revenue$0000 View About Inspire Medical Systems Inspire Medical Systems specializes in innovative treatments for obstructive sleep apnea within the medical device industry. The company offers a mask-free, implantable system that provides an alternative to CPAP therapy for individuals who...
The combination of atomoxetine and oxybutynin (ato-oxy) is being investigated in an ongoing double-blind clinical trial of obstructive sleep apnea in children with DS. Preliminary results suggest that ato-oxy is typically safe in children with DS. The most common adverse events to date have been...